Juli R Bago
Overview
Explore the profile of Juli R Bago including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
619
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Motais B, Charvatova S, Walek Z, Hajek R, Bago J
Cells
. 2023 Dec;
12(23).
PMID: 38067177
Multiple myeloma (MM) has witnessed improved patient outcomes through advancements in therapeutic approaches. Notably, allogeneic stem cell transplantation, proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies have contributed to enhanced quality...
2.
Charvatova S, Motais B, Czapla J, Cichon T, Smolarczyk R, Walek Z, et al.
Cells
. 2023 Feb;
12(3).
PMID: 36766789
Myeloma bone disease (MBD) is one of the major complications in multiple myeloma (MM)-the second most frequent hematologic malignancy. It is characterized by the formation of bone lesions due to...
3.
Ferrer-Curriu G, Soler-Botija C, Charvatova S, Motais B, Roura S, Galvez-Monton C, et al.
Biomed Pharmacother
. 2022 Dec;
158:114061.
PMID: 36495661
Fibrosis is present in an important proportion of myocardial disorders. Injury activates cardiac fibroblasts, which deposit excess extracellular matrix, increasing tissue stiffness, impairing cardiac function, and leading to heart failure....
4.
Mercer-Smith A, Jiang W, Bago J, Valdivia A, Thang M, Woodell A, et al.
Mol Cancer Ther
. 2021 Aug;
20(11):2291-2301.
PMID: 34433662
Converting human fibroblasts into personalized induced neural stem cells (hiNSC) that actively seek out tumors and deliver cytotoxic agents is a promising approach for treating cancer. Herein, we provide the...
5.
Jiang W, Yang Y, Mercer-Smith A, Valdivia A, Bago J, Woodell A, et al.
Sci Adv
. 2021 Jun;
7(24).
PMID: 34108203
Engineered tumor-homing neural stem cells (NSCs) have shown promise in treating cancer. Recently, we transdifferentiated skin fibroblasts into human-induced NSCs (hiNSC) as personalized NSC drug carriers. Here, using a SOX2...
6.
Motais B, Charvatova S, Walek Z, Hrdinka M, Smolarczyk R, Cichon T, et al.
Cells
. 2021 Apr;
10(5).
PMID: 33919155
Cellular immunotherapy is becoming a new pillar in cancer treatment after recent striking results in different clinical trials with chimeric antigen receptor T cells. However, this innovative therapy is not...
7.
Carey-Ewend A, Hagler S, Bomba H, Goetz M, Bago J, Hingtgen S
Tissue Eng Part A
. 2020 Oct;
PMID: 33085922
Engineered neural stem cells (NSCs) have recently emerged as a promising therapy. Acting as a tumor-homing drug-delivery system, NSCs migrate through brain tissue to seek out primary and invasive tumor...
8.
Carey-Ewend A, Hagler S, Bomba H, Goetz M, Bago J, Hingtgen S
Tissue Eng Part A
. 2020 Sep;
27(13-14):857-866.
PMID: 32907497
Engineered neural stem cells (NSCs) have recently emerged as a promising therapy. Acting as a tumor-homing drug-delivery system, NSCs migrate through brain tissue to seek out primary and invasive tumor...
9.
Sahinbegovic H, Jelinek T, Hrdinka M, Bago J, Turi M, Sevcikova T, et al.
Cancers (Basel)
. 2020 Jul;
12(7).
PMID: 32635428
Cell-to-cell communication is a fundamental process in every multicellular organism. In addition to membrane-bound and released factors, the sharing of cytosolic components represents a new, poorly explored signaling route. An...
10.
Motais B, Charvatova S, Hrdinka M, Simicek M, Jelinek T, Sevcikova T, et al.
Cancers (Basel)
. 2020 May;
12(5).
PMID: 32456165
Hematological malignancies comprise over a hundred different types of cancers and account for around 6.5% of all cancers. Despite the significant improvements in diagnosis and treatment, many of those cancers...